Skip to search formSkip to main contentSkip to account menu

Y-39983

National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
Purpose To discover novel therapies that lower IOP by increasing aqueous humor outflow facility, ex vivo ocular perfusion systems… 
Highly Cited
2014
Highly Cited
2014
PURPOSE To investigate the molecular mechanism of Rho-associated kinase (ROCK) inhibitors Y-27632 and Y-39983 on corneal… 
Highly Cited
2014
Highly Cited
2014
PURPOSE To determine whether ROCK inhibition for the treatment of glaucoma can be improved by using novel, locally acting Rho… 
2013
2013
Y-39983, a selective Rho-associated kinase (ROCK) inhibitor, promotes axonal regeneration of damaged retinal ganglion… 
2013
2013
Objective: Rho-associated kinase (ROCK) is a serine/threonine kinase and a major downstream effector of the small GTP-binding… 
2011
2011
PurposeIn normotensive eyes, reduced ocular blood flow can lead to glaucoma pathogenesis. Drugs that reduce intraocular pressure… 
Highly Cited
2011
Highly Cited
2011
Purpose: To investigate the effects of Y-39983, a selective Rho-associated coiled coil-forming protein kinase inhibitor, on blood… 
Highly Cited
2011
Highly Cited
2011
Purpose The outflow facility for aqueous humor across the trabecular meshwork (TM) is enhanced by agents that oppose the… 
2009
2009
PURPOSE Goals of this study were to determine if pharmacological or genetic inhibition of Rho-associated coiled coil containing…